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I Short Report I 
Problems in the therapy of mixed 
malarial infections: a case of 
infection with Plasmodium 
falciparum and P. malariae treated 
with mefloquine and halofantrine 
F. J. Hess, H. D. A. Kilian, H. D. Nothdurft and 
T. ~öscher Department of Tropical Medicine and 
Infectwus Diseases, University of Munich, Munich, 
Germany 
Mixed malarial infections of Plasmodium falciparum 
and P. malariae are not uncommon but they may often 
be overlooked l?ecause there is a tendency for P. falcipa-
"fm .to predommate and the parasitaemia with P. mala-
nae IS usually very low. 
Therapy of cases of mixed infections with P. falcipa-
rum !lnd P. malaria~, P. vivax or P. ovale should clearly 
~e almed at P. falctparum as the potentially lethai infec-
tIO~S a~ent (COOK, 1988), .followed by a course of prima-
qume m the case of P. vlvax or P. ovale. For non-im-
mune subjects, mefloquine and halofantrine are the 
currently .recommende~ ~rst line drugs for uncompli-
c~ted fa1clparum malana Inlported from African coun-
tnes where chloroquine resistance is common (WHO 
1992). ' 
However, very limited information is available con-
cerning the efficacy of these 2 drugs in the treatment of 
quartan malaria. DIXON and co-workers (1983) have suc-
cessfully used mefloquine to treat a case of P. malariae 
and they reported rather slow resolution of fever and 
parasitaemia. Similarly, WEINKE et al. (1993) reported 
the successful treatment of 2 cases of P. malariae infec-
tion. (one mixed with P. falciparum) with halofantrine, 
but In both reports the follow-up period was only 28 d. 
B:ere we report a patient with a mixed infection of P. 
fal~lparum and P. malariae treated initially with meflo-
qUIne and subsequently with halofantrine; the possible 
failure ofboth drugs is discussed. 
In July 1991 a 46 years old German woman presented 
at ~ peripheral hospital in qermany with fever (39·2°C), 
chills, .headache and anoreXla of 3 d duration, 12 d after 
returrung from 2 weeks' holiday in Kenya. She denied 
~aving taken any malaria chemoprophylaxis or anti-mala-
nal treatment. The diagnosis of fa1ciparum malaria was 
made by exarnination of blood films which had been sent 
to our institute for confirrnation. The initial parasitaemia 
was 3% (136 OOO/IlL). Other than a thrombocytopenia of 
128 OOO/IlL. there was no abnormality or sign of compli-
cated malana. Consequently she was treated with meflo-
quine in a total dose of 1500 mg (750 mg followed by 500 
mg 6 h later and 250 ~g after a further 12 h), equivalent 
to 20 mg/kg body wel~ht. She did not vomit after taking 
the drug. Fever had dlsappeared by day 4 and parasitae-
mia by day 6. The patient was discharged on day 7, clini-
cally fully recovered. 
In October 1991 (78 d later) the patient presented 
again ~t the same hospital with fever (40°C), shivering 
and chilis. She had not been abroad since her last hospi-
tal admission. Suspecting a P. falciparum recrudescence 
treatment with halofantrine was started immediately: 
However, all blood slides sent to us clearly revealed a P. 
malariae monoinfection. She was given 3 doses of halo-
fan trine, 500 mg, orally at intervals of 6 h. Again there 
was no vomiting and recovery was uneventful. Clearance 
of fever and parasitaemia occurred at days 3 and 4 re-
spectively. Treatment was repeated one week after the 
initial course, using the same dose of halofantrine. 
In January 1992 (106 d after her first admission) the 
patient presented a third time at the same hospital with 
fever and headache. Again P. malariae was detected in 
thick and thin blood films sent to us, although she had 
not travelIed to a malaria endemic area since her last ad-
mis~ion. Apart from mild splenomegaly no other abnor-
mahty could be found and again she was treated with 2 
full courses of halofantrine with an interval of one week. 
Her ~ever and para~itae~ia cleared by days 2 and 8 re-
spectIvely. After this thlrd treatment the patient was fi-
nally referred to us for further counselling and was ad-
vised to consult us directly in case of further symptoms. 
!o date (March 1993,410 d after her last therapy) she is 
In good health, no further episode of fever attributable to 
malarial infection has occurred, and repeated blood films 
have always been negative for Plasmodium. 
In this patient we observed a recrudescence of P. ma-
lariae infection more than 2 months after mefloquine 
tre~tment. There ca~ be no doubt that the drug was suf-
ficlently absorbed, smce concomitant infection with P 
falciparum was cleared promptly. Therefore one migh~ 
conclude that mefloquine failed to eradicate a very low 
parasitaemia of P. malariae, which had been overlooked 
at the init~al examiJ?-ation. Alternatively it is possible that 
P. ma!a~~e parasltes were not present in peripheral 
blood InltIally, due to a longer incubation period and 
when p~rasitaemia developed later, the plasma l:vel of 
mefloqume was no longer sufficient to clear the infection 
completely. 
In ~he case of ha!ofantrine, on the other hand, poor ab-
sorptIon resultIng m low plasma concentrations may have 
caused the first. t~erapy failure even though a second 
course was adffilrustered after one week, which in fa1ci-
parum malaria is thought to have almost 100% efficacy in 
non-immune subjects (NOTHDURFT et al., 1993). This 
explanation appears to be more likely than true halofan-
trine resistance. Such a view is also supported by the fact 
that the s~cond treatment with halofantrine has obviously 
resulted In complete cure. Nevertheless, it cannot be 
ruled out completely that the plasma level of halofantrine 
needed for effective treatment of P. malariae is higher 
than that for P. falciparum. 
Interestingly, both clinical episodes of P. malariae 
monoinfection in our patient occurred more than 2 
months after the initial mefloquine and halofantrine 
treatment (78 and 106 d, respectively) and would not 
have been detected in the usual28 d observation period. 
We conclude that double infections with P. falciparum 
and P. malanae may pose some therapeutic difficulties 
when treated with mefloquine or halofantrine. Since 
~here has been litt!e experience to date with these 2 drugs 
In quartan malana, recrudescence of P. malariae after 
such mixed infections should be treated with chloro-
quine, w~ich remains the treatment of choice. It is par-
~lcularly Important to make a thorough species diagnosis 
In such cases before treatment is given. 
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